Showing results (1301-1310 of 1,368) with videos related to

Sort By:
Pageof 137
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2020
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple MyelomaPaul G Richardson, Albert Oriol, Alessandra Larocca, et al.
Haematologica|February 6, 2014
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaMonika Engelhardt, Evangelos Terpos, Martina Kleber, et al.
The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.
Sensors (Basel, Switzerland)|June 2, 2021
Field-Portable Microplastic Sensing in Aqueous Environments: A Perspective on Emerging TechniquesMorgan G Blevins, Harry L Allen, Beckett C Colson, et al.
Annals of Surgery|May 27, 2017
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver MetastasesKristoffer W Brudvik, Robert P Jones, Felice Giuliante, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
The Journal of Experimental Medicine|June 15, 2011
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activationGiulia Fabbri, Silvia Rasi, Davide Rossi, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2019
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with GlioblastomaPatrick Y Wen, David A Reardon, Terri S Armstrong, et al.
The Lancet. Haematology|August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trialSara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.
Pageof 137